---
title: "NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295793397.md"
description: "In Vancouver, British Columbia on August 13, 2026, NervGen, a company listed on NASDAQ under the ticker NGEN, shared its financial performance for the quarter concluding on June 30, 2026. The company, a leading late-stage clinical biopharmaceutical firm specializing in innovative neuroreparative treatments for spinal cord injury (SCI) and various neurotraumatic and neurologic ailments, also disclosed recent developments in their business operations."
datetime: "2026-08-13T11:33:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295793397.md)
  - [en](https://longbridge.com/en/news/295793397.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295793397.md)
generator: "portal-rs"
---

# NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

In Vancouver, British Columbia on August 13, 2026, NervGen, a company listed on NASDAQ under the ticker NGEN, shared its financial performance for the quarter concluding on June 30, 2026. The company, a leading late-stage clinical biopharmaceutical firm specializing in innovative neuroreparative treatments for spinal cord injury (SCI) and various neurotraumatic and neurologic ailments, also disclosed recent developments in their business operations.

### Related Stocks

- [NGEN.US](https://longbridge.com/en/quote/NGEN.US.md)

## Related News & Research

- [HPS/PayMedix Named a 2026 Best and Brightest Company to Work For](https://longbridge.com/en/news/298358823.md)
- [Quoin says FDA grants rare pediatric disease designation for QRX003 in peeling skin syndrome](https://longbridge.com/en/news/298320213.md)
- [Essex Property Trust declares Q3 2026 dividend of R$ 0.89 per unit](https://longbridge.com/en/news/298322539.md)
- [OncoZenge UCLA oral mucositis patient engagement study to be presented at ASTRO meeting](https://longbridge.com/en/news/298419720.md)
- [Curanex Pharmaceuticals executes 1-for-20 reverse stock split](https://longbridge.com/en/news/298072376.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**